vTv Therapeutics Inc. Class A Common Stock
$31.80
$0.40 (+1.27%)
$31.05Day Range$32.09
Key Statistics
Market Cap
$124.15M
Shares Outstanding
4.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 30, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$31.15
Day High
$32.09
Day Low
$31.05
Volume
74.4K
VWAP
$31.65
Prev Close
$31.40
Transactions
--
Acc. Volume
--
About vTv Therapeutics Inc. Class A Common Stock
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
PHARMACEUTICAL PREPARATIONSSIC 283426 employees3980 PREMIER DR, HIGH POINT, NC, 27265336-841-0300IPO Jul 30, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001641489
- Composite FIGI
- BBG009DT9XJ0
- Share Class FIGI
- BBG009DT9XK8
- Ticker Root
- VTVT
- SIC Code
- 2834
About vTv Therapeutics Inc. Class A Common Stock (VTVT) Stock
vTv Therapeutics Inc. Class A Common Stock (VTVT) closed the 2026-09-18 session at $31.80, up 1.27% versus the previous close (+0.40). The stock opened at $31.15 and traded between $31.05 and $32.09 during that session. Session trading volume was 74K shares. The volume-weighted average price (VWAP) is $31.65.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
vTv Therapeutics Inc. Class A Common Stock has a market capitalization of $124.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VTVT is listed on the XNAS exchange. The company employs approximately 26 people. vTv Therapeutics Inc. Class A Common Stock is headquartered in HIGH POINT, NC. The recorded listing date is 2015-07-30.
On this page you can find market VTVT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.